Characteristics of Placebo Responders in Pediatric Clinical Trials of Attention-Deficit/Hyperactivity Disorder

• Published in: Journal of the American Academy of Child and Adolescent Psychiatry Vol. 48; no. 12; pp. 1165 - 1172
• Main Authors: Newcorn, Jeffrey H, Sutton, Virginia K, Zhang, Shuyu, Wilens, Timothy, Kratochvil, Christopher, Emslie, Graham J, D'Souza, Deborah N, Schuh, Leslie M, Allen, Albert J
• Format: Journal Article
• Language: English
• Published: United States Elsevier 01.12.2009
• Subjects: Adolescent; Adolescents; Adrenergic Uptake Inhibitors - adverse effects; Adrenergic Uptake Inhibitors - therapeutic use; Anxiety Disorders - diagnosis; Anxiety Disorders - drug therapy; Anxiety Disorders - psychology; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity - diagnosis; Attention Deficit Disorder with Hyperactivity - drug therapy; Attention Deficit Disorder with Hyperactivity - psychology; Attention Deficit Hyperactivity Disorder; Child; Children; Comorbidity; Data Analysis; Depressive Disorder, Major - diagnosis; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - psychology; Double-Blind Method; Drug Therapy; Female; Humans; Male; Multicenter Studies as Topic; Outcomes of Treatment; Patients; Personality Assessment; Placebo Effect; Prediction; Propylamines - adverse effects; Propylamines - therapeutic use; Randomized Controlled Trials as Topic; Rating Scales; Research Design; Science Education; Stimulants

Objective: Understanding placebo response is a prerequisite to improving clinical trial methodology. Data from placebo-controlled trials of atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) were analyzed to identify demographic and clinical...